ZyVersa is incorporated in the state of Delaware.

ZyVersa became a public company in December, 2022.

ZyVersa is a clinical stage specialty biopharmaceutical company with two licensed proprietary product platforms. Our focus is on renal and inflammatory diseases which have a global total addressable market of around $14.5 billion and $65 billion, respectively. The lead candidate in our renal pipeline is Phase 2a-ready Cholesterol Efflux Mediator™ VAR 200, which mediates removal of excess renal cholesterol and lipids that damage the kidneys. VAR 200 is expected to reduce proteinuria and delay disease progression. For treatment of inflammatory diseases, ZyVersa is developing a highly differentiated monoclonal antibody that inhibits inflammasome ASC (IC 100). By targeting ASC, IC 100 potentially inhibits twelve or more types of inflammasomes, not just NLRP3. This is expected to better control inflammation in diseases that are triggered by activation of more than one type of inflammasome. Likewise, by targeting ASC, IC 100 inhibits inflammasome formation and initiation of the inflammatory cascade. IC 100 also inhibits intra- and extracellular ASC specks which amplify and propagate inflammation in inflammatory diseases. IC 100 has strong indication expansion potential in a broad range of CNS and other inflammatory diseases.

ZyVersa’s executive management team can be viewed here.

ZyVersa’s board of directors can be viewed here.

ZyVersa has issued & pending patents in and outside the US for both its renal and inflammatory product platforms. New filings are planned throughout the development process for each platform.

ZyVersa is traded on the OTCQB Market under the symbol, ZVSA.

Continental Stock Transfer & Trust
1 State Street, 30th Floor
New York, NY 10004-1561
212-509-4000 or 800-509-5586
Email: cstmail@continentalstock.com
www.continentalstock.com

For questions about stock, please contact our transfer agent, Continental Stock Transfer & Trust. The transfer agent’s address is 1 State Street, 30th Floor, New York, NY 10004-1561, and the telephone number is 212-509-4000 or 800-509-5586.

ZyVersa’s financial information can be viewed here.

Zyversa’s fiscal quarters end on March 31, June 30, September 30, and December 31.

ZyVersa has established an independently operated, anonymous, and confidential hotline for reporting suspected violations of laws, regulations, or ZyVersa policies. The hotline can be accessed 24 hours a day, 7 days a week as follows: (1) Secure Web Form at https://www.whistleblowerservices.com/ZyVersa or (2) Secure Phone Line at 833-636-3075. For more information, please refer to ZyVersa’s Whistle Blower Policy, which can be viewed here.

CBIZ CPAs P.C.
730 3rd Ave, 11th Floor
New York, NY 10017

Thompson Hine
300 Madison Avenue, 27th Floor
New York, New York 10017-6232
Phone: 212-344-5680
Website: www.thompsonhine.com